

ForPatients

by Roche

Macular Degeneration Age-Related Macular Degeneration Geographic Atrophy

The long-term study of a new medicine (galegenimab) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

A Study Assessing the Long-Term Safety and Tolerability of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Trial Status
Terminated

Trial Runs In
1 Countries

Trial Identifier
NCT04607148 GR42558

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial investigated a new medicine called “galegenimab.” People with a type of eye disease, “geographic atrophy secondary to age-related macular degeneration,” joined this study to find out if galegenimab treatments were safe and tolerable when given over a long time. Injections were given in the study eye, once every 4 or 8 weeks. The study treatment was planned for about 3 years. People underwent detailed eye examinations throughout the study. They were monitored for side effects, taking into consideration their nature, frequency, and severity.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)
Sponsor

Phase 2
Phase

NCT04607148 GR42558
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=60 Years

Healthy Volunteers
No
